A Phase 1/1b Study of IAM1363 in HER2 Cancers

• Status: RECRUITING
• Trial end date: 2028-03-01

Summary

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

• Phase: PHASE1

Details

• Lead Sponsor: Iambic Therapeutics, Inc